Better Health for All

Aurinia Pharmaceuticals' primary product, LUPKYNIS, is the first FDA-approved oral therapy for active lupus nephritis, a serious autoimmune disease, aiming to prevent irreversible kidney damage.

While the product offers exceptional health benefits, it carries a Boxed Warning for increased risk of cancer and infection, along with other serious side effects. For price accessibility, 97% of LUPKYNIS shipments to commercially insured, Medicaid, or Medicare patients cost $10 or less in 2022, with a $0 copay program for eligible commercial patients. The company supports vulnerable populations by focusing on autoimmune diseases prevalent in racial-ethnic minority women and offering patient assistance programs. Risk transparency is strong, with detailed disclosures of LUPKYNIS's Boxed Warning and side effects. The company invests in a robust clinical development program for LUPKYNIS and offers options for financial assistance. Aurinia Alliance provides personalized support, educational tools, and Nurse Case Managers. The company also promotes preventative health measures like routine testing and sun protection. Data privacy is addressed with an Information Security Policy aligned with GDPR, and 100% of employees completed data privacy training in FY2023. Aurinia collaborated with 42 advocacy organizations and connected with 2,215 people living with SLE/LN in 2023 for education. Clinical studies for LUPKYNIS involved over 350 people across different races and ethnicities.

Fair Money & Economic Opportunity

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies, not a financial institution. The ethical value 'Fair Money & Economic Opportunity' is designed to assess companies that lend, insure, move, or store money, evaluating their practices related to financial services, lending, and economic inclusion. As Aurinia's core business lies outside financial services, all KPIs within this rubric are not applicable. The provided articles discuss the cost-effectiveness of its medication, LUPKYNIS, and patient support programs like Aurinia Alliance, which assist patients with understanding insurance and funding options for their treatment.

However, these activities do not constitute offering lending or deposit services, managing customer financial data, or providing general financial literacy programs as defined by the rubric for financial institutions. Therefore, no specific, concrete data points relevant to the financial services KPIs could be found or applied.

Fair Trade & Ethical Sourcing

Zero incidents of forced or child labour were identified in Aurinia's operations or supply chain during FY2024, and no specific incidents were reported for 2022.

The company complies with the Fighting Against Forced Labour and Child Labour in Supply Chains Act (Canada), and audits by Aurinia and the FDA revealed no instances of forced or child labour. In FY2024, Aurinia standardized language in its master service agreements, requests for proposals, service agreements, consultancy agreements, and other vendor contracts to include representations and warranties that none of its vendors utilize forced or child labour.

Honest & Fair Business

No specific, concrete data points were found for any of the 'Honest & Fair Business' KPIs. A securities class action lawsuit (Ortmann v. Aurinia Pharmaceuticals Inc.) was filed against Aurinia Pharmaceuticals, alleging misleading statements regarding its drug LUPKYNIS.

However, the US District Court for the District of Maryland dismissed this case with prejudice on August 13, 2024, finding that the company's disclosures were sufficient and that the plaintiff failed to adequately plead material misrepresentations or omissions. This outcome indicates no regulatory fines or findings of material misrepresentation from this specific legal action. No information was provided regarding transparency index scores, whistleblower policies, financial restatements, audit coverage, ESG controversy scores, complaint resolution times, board conflict-free percentages, anti-corruption policies, or third-party verification.

Planet-Friendly Business

Aurinia Pharmaceuticals reported total Scope 1, 2, and 3 greenhouse gas emissions of 4,562 metric tons CO2e, representing a 7.2% reduction.

The company's waste diversion rate is 8.3%. It recorded zero critical observations in three regulatory inspections. The company conducted 18 environmental impact assessments.

Respect for Cultures & Communities

The provided articles state that Aurinia Pharmaceuticals awarded 18 community impact grants.

However, this information does not specify if these grants constitute formal partnerships with indigenous or local community groups, nor does it indicate the percentage of revenue reinvested or allocated to cultural preservation or community development. No other specific, quantifiable data points are available for any of the KPIs related to Respect for Cultures & Communities.

Safe & Smart Tech

The company reported no data breaches materially affecting it in 2024, and no known incidents are reasonably likely to materially affect the company.

No incidents of unauthorized data use were reported. The company's Information Security Policy is designed to align with GDPR. Employee and contractor security training is conducted regularly, with metrics tracked to assess security posture. The company utilizes Microsoft tools, a cloud IT strategy, and a 24/7 cybersecurity monitoring service, employing a layered strategy for managing cybersecurity risks, including third-party service providers.

Zero Waste & Sustainable Products

Aurinia Pharmaceuticals Inc. has implemented waste reduction initiatives, including its Rockville, Maryland office being LEED Silver certified, which contributes to less resource consumption and waste generation.

The company has also initiated data collection across its facilities, manufacturing, supply chain, and procurement teams to assess its environmental impact.